271 related articles for article (PubMed ID: 29100460)
1. Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.
Birnie KA; Prêle CM; Thompson PJ; Badrian B; Mutsaers SE
Oncotarget; 2017 Sep; 8(44):78193-78207. PubMed ID: 29100460
[TBL] [Abstract][Full Text] [Related]
2. Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approaches-a narrative review.
Zolondick AA; Gaudino G; Xue J; Pass HI; Carbone M; Yang H
Precis Cancer Med; 2021 Sep; 4():. PubMed ID: 35098108
[TBL] [Abstract][Full Text] [Related]
3. Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.
Fortarezza F; Pezzuto F; Marzullo A; Cavone D; Romano DE; d'Amati A; Serio G; Vimercati L
Front Oncol; 2022; 12():823839. PubMed ID: 35223506
[TBL] [Abstract][Full Text] [Related]
4. New vistas in malignant mesothelioma: MicroRNA architecture and NRF2/MAPK signal transduction.
Gandhi M; Nair S
Life Sci; 2020 Sep; 257():118123. PubMed ID: 32710945
[TBL] [Abstract][Full Text] [Related]
5. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure.
Roberts HC; Patsios DA; Paul NS; DePerrot M; Teel W; Bayanati H; Shepherd F; Johnston MR
J Thorac Oncol; 2009 May; 4(5):620-8. PubMed ID: 19357540
[TBL] [Abstract][Full Text] [Related]
6. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
[TBL] [Abstract][Full Text] [Related]
7. Circulating Epigenetic Biomarkers in Malignant Pleural Mesothelioma: State of the Art and critical Evaluation.
Ferrari L; Carugno M; Mensi C; Pesatori AC
Front Oncol; 2020; 10():445. PubMed ID: 32318342
[TBL] [Abstract][Full Text] [Related]
8. Plasmatic extracellular vesicle microRNAs in malignant pleural mesothelioma and asbestos-exposed subjects suggest a 2-miRNA signature as potential biomarker of disease.
Cavalleri T; Angelici L; Favero C; Dioni L; Mensi C; Bareggi C; Palleschi A; Rimessi A; Consonni D; Bordini L; Todaro A; Bollati V; Pesatori AC
PLoS One; 2017; 12(5):e0176680. PubMed ID: 28472171
[TBL] [Abstract][Full Text] [Related]
9. New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma.
Rossini M; Rizzo P; Bononi I; Clementz A; Ferrari R; Martini F; Tognon MG
Front Oncol; 2018; 8():91. PubMed ID: 29666782
[TBL] [Abstract][Full Text] [Related]
10. [Malignant mesothelioma in Basse-Normandie, a French population study. Descriptive analysis, prognostic factors and survival].
Desoubeaux N; Bouvier V; Gervais R; Galateau-Salle F; Thibon P; Leplumey T; Herbert C; Lecherbonnier Y; Daviet JP; Letourneux M
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):523-9. PubMed ID: 11845101
[TBL] [Abstract][Full Text] [Related]
11. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
12. [Immunological aspects of asbestos-related diseases].
Kanceljak-Macan B
Arh Hig Rada Toksikol; 2009 Nov; 60 Suppl():45-50. PubMed ID: 20853778
[TBL] [Abstract][Full Text] [Related]
13. [Malignant peritoneal mesothelioma].
Scripcariu V; Dajbog E; Lefter L; Ferariu D; Pricop A; Grigoraş M; Dragomir C
Chirurgia (Bucur); 2006; 101(6):641-6. PubMed ID: 17283842
[TBL] [Abstract][Full Text] [Related]
14. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
Sterman DH; Albelda SM
Respirology; 2005 Jun; 10(3):266-83. PubMed ID: 15955137
[TBL] [Abstract][Full Text] [Related]
15. Malignant peritoneal mesothelioma: a review.
Kim J; Bhagwandin S; Labow DM
Ann Transl Med; 2017 Jun; 5(11):236. PubMed ID: 28706904
[TBL] [Abstract][Full Text] [Related]
16. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
17. Malignant peritoneal mesothelioma: quantitative analysis of asbestos burden.
Kurimoto R; Kishimoto T; Nagai Y; Takazawa H; Sakaue N; Shinohara Y; Hiroshima K
Pathol Int; 2009 Nov; 59(11):823-7. PubMed ID: 19883435
[TBL] [Abstract][Full Text] [Related]
18. Primary Peritoneal Mesothelioma: Diagnostic Challenges of This Lethal Imposter.
Dusseault SK; Okobi OE; Thakral N; Sankar V; Gunawardene I; Dawkins B; Abu Y; Davis B
Case Rep Gastroenterol; 2022; 16(3):588-594. PubMed ID: 36636360
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: biology, diagnosis and therapeutic approaches.
Tomasetti M; Amati M; Santarelli L; Alleva R; Neuzil J
Curr Mol Pharmacol; 2009 Jun; 2(2):190-206. PubMed ID: 20021458
[TBL] [Abstract][Full Text] [Related]
20. Genomics and Epigenetics of Malignant Mesothelioma.
Sage AP; Martinez VD; Minatel BC; Pewarchuk ME; Marshall EA; MacAulay GM; Hubaux R; Pearson DD; Goodarzi AA; Dellaire G; Lam WL
High Throughput; 2018 Jul; 7(3):. PubMed ID: 30060501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
